Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleCannabis use amongst patients with inflammatory bowel disease.
Author(s)Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H.
Journal, Volume, IssueEur J Gastroenterol Hepatol. 2011 Oct;23(10):891-6.
Major outcome(s)Cannabis use is frequent in patients with chronic intestinal inflammation
IndicationGastrointestinal disorder;InflammationAbstract
MedicationCannabis

BACKGROUND: Experimental evidence suggests the endogenous cannabinoid system may
protect against colonic inflammation, leading to the possibility that activation
of this system may have a therapeutic role in inflammatory bowel disease (IBD).
Medicinal use of cannabis for chronic pain and other symptoms has been reported
in a number of medical conditions. We aimed to evaluate cannabis use in patients
with IBD. METHODS: One hundred patients with ulcerative colitis (UC) and 191
patients with Crohn's disease (CD) attending a tertiary-care outpatient clinic
completed a questionnaire regarding current and previous cannabis use,
socioeconomic factors, disease history and medication use, including
complimentary alternative medicines. Quality of life was assessed using the
short-inflammatory bowel disease questionnaire. RESULTS: A comparable proportion
of UC and CD patients reported lifetime [48/95 (51%) UC vs. 91/189 (48%) CD] or
current [11/95 (12%) UC vs. 30/189 (16%) CD] cannabis use. Of lifetime users,
14/43 (33%) UC and 40/80 (50%) CD patients have used it to relieve IBD-related
symptoms, including abdominal pain, diarrhoea and reduced appetite. Patients were
more likely to use cannabis for symptom relief if they had a history of abdominal
surgery [29/48 (60%) vs. 24/74 (32%); P=0.002], chronic analgesic use [29/41
(71%) vs. 25/81 (31%); P<0.001], complimentary alternative medicine use [36/66
(55%) vs. 18/56 (32%); P=0.01] and a lower short inflammatory bowel disease
questionnaire score (45.1±2.1 vs. 50.3±1.5; P=0.03). Patients who had used
cannabis [60/139 (43%)] were more likely than nonusers [13/133 (10%); P<0.001 vs.
users] to express an interest in participating in a hypothetical therapeutic
trial of cannabis for IBD. CONCLUSION: Cannabis use is common amongst patients
with IBD for symptom relief, particularly amongst those with a history of
abdominal surgery, chronic abdominal pain and/or a low quality of life index. The
therapeutic benefits of cannabinoid derivatives in IBD may warrant further
exploration.

Route(s)Inhalation
Dose(s)
Duration (days)
Participants100 patients with ulcerative colitis (UC) and 191 patients w
DesignSurvey
Type of publicationMedical journal
Address of author(s)The IBD Clinic, Mount Sinai Hospital, Toronto, Ontario, Canada bIntestinal Failure Unit, Salford Royal NHS Foundation Trust, Salford, UK.
Full text

[Back to Overview]  [IACM Homepage]


up